Tesamorelin

What the evidence says

Graded on the compound profile, not restated here.

The one growth-hormone-axis peptide in this group with a genuine FDA approval — proven in large trials to reduce excess visceral abdominal fat in people with HIV-associated lipodystrophy.

AEstablishedVisceral adipose tissue reduction (HIV lipodystrophy)FDA-approved and proven in large randomized trials.
BSupportedTriglyceride / lipid improvement (HIV lipodystrophy)Consistent secondary-endpoint benefit in the pivotal trials.
CPreliminaryLiver fat / NAFLD reductionPromising randomized data in HIV, not an approved indication.
UUnknownFat loss / body composition in non-HIV or general anti-aging useUnknown — the evidence base is HIV-specific and does not transfer.

Full Tesamorelin evidence profile →

Tesamorelin is the outlier in this catalog: it holds a real FDA approval, and the compound profile grades visceral fat reduction in HIV-associated lipodystrophy at A — the highest grade anything here carries.

That approval is also the reason to be most careful buying it.

The approval belongs to Egrifta, not to the molecule

An FDA approval covers a specific product from a specific manufacturer, made under documented conditions, with established identity, potency, and sterility. Egrifta has that. A vial bought as “tesamorelin” from a research supplier does not, and none of the approval’s guarantees travel with the name.

The A grade describes what the approved product achieved in trials of a defined population. Applying it to an unverified vial requires assuming identity, potency, and sterility that nobody has demonstrated for the item you received.

Approval raises counterfeit incentive

A molecule with a real indication and a high retail price is worth substituting. That makes mass-spec identity on a lot-matched certificate more important here than for compounds nobody has reason to fake, not less.

Strength is the second check. This catalog prices tesamorelin by vial size, so under-loading is the straightforward way to cut cost. Net peptide content on the COA is the number that catches it; gross vial weight is not.

The evidence article covers what the approved product actually demonstrated, and for whom.

Before you buy

Understand that an approved indication belongs to Egrifta, a specific manufactured product. A research vial is not that drug and inherits none of its guarantees.

Require mass-spec identity and a lot-matched COA. The approval makes this molecule attractive to counterfeit.

Confirm net peptide content and stated strength — price scales with strength and is the obvious place to under-deliver.

Sterility is not implied by purity, and is not established by any COA in this market.